Cougar Biotechnology cougarbiotechnology.com


Public list: Pharma Startups (4743) Cancer Therapeutics (1146)

Cougar Biotechnology aims to in-license and develop oncology drugs. Cougar's oncology portfolio includes CB7630, a targeted enzyme inhibitor, which is currently being tested in Phase II clinical trials in prostate cancer; other products are being tested for hematological and solid tumors. In 2006, Cougar completed a reverse merger with public shell company, and became public.

Cougar Biotechnology aims to in-license and develop oncology drugs. Cougar's oncology portfolio includes CB7630, a targeted enzyme inhibitor, which is currently being tested in Phase II clinical trials in prostate cancer; other products are being tes...Show all

Company (IPO / Went public)

Phone: 310-943-8040

Fax:

10990 Wilshire Boulevard
Suite 1200
Los Angeles, 90024
California, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Cougar Biotechnology $39.7M Feb 21, 2007
Poniard Pharmaceuticals $99.1M Apr 18, 2006
Cephalon $84.5M Feb 18, 1999
See all 14 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Cougar Biotechnology Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 12 investors

Competitors

Company Status Description Investors
See all 14 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)